Search research articles
Contact Us
Filters
Showing results (441-450 of 578) with videos related to
Page
of 58
Sort By:
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
Cancers
|
November 25, 2023
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
Hannah Woopen, Maren Keller, Dario Zocholl, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 22, 2014
Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting
Frédéric Amant, Michael J Halaska, Monica Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
The Lancet. Oncology
|
March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2022
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Jitka Fucikova, Michal Hensler, Lenka Kasikova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
Page
of 58
Search research articles
Search
Showing results (441-450 of 578) with videos related to
Sort By:
Page
of 58
Bulletin Du Cancer
|
March 26, 2023
Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer
Philipp Harter, Gerhard Bogner, Luis Chiva, et al.
Cancers
|
November 25, 2023
Side Effects from Cancer Therapies and Perspective of 1044 Long-Term Ovarian Cancer Survivors-Results of Expression VI-Carolin Meets HANNA-Holistic Analysis of Long-Term Survival with Ovarian Cancer: The International NOGGO, ENGOT, and GCIG Survey
Hannah Woopen, Maren Keller, Dario Zocholl, et al.
Cancer Medicine
|
September 26, 2024
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, et al.
European Journal of Cancer (Oxford, England : 1990)
|
October 1, 2021
Population-adjusted indirect treatment comparison of the SOLO1 and PAOLA-1/ENGOT-ov25 trials evaluating maintenance olaparib or bevacizumab or the combination of both in newly diagnosed, advanced BRCA-mutated ovarian cancer
Ignace Vergote, Isabelle Ray-Coquard, Daniel M Anderson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 22, 2014
Gynecologic cancers in pregnancy: guidelines of a second international consensus meeting
Frédéric Amant, Michael J Halaska, Monica Fumagalli, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 9, 2016
Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNA-Expressing Platinum-Resistant Ovarian Cancer (PENELOPE)
Christian Kurzeder, Isabel Bover, Frederik Marmé, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 18, 2024
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics
Stanislas Quesada, Frédérique Penault-Llorca, Xavier Matias-Guiu, et al.
The Lancet. Oncology
|
March 21, 2021
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
Andrés Poveda, Anne Floquet, Jonathan A Ledermann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2022
An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors
Jitka Fucikova, Michal Hensler, Lenka Kasikova, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 28, 2023
PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial
Liselore Loverix, Ignace Vergote, Pieter Busschaert, et al.
Page
of 58